Table 1

Baseline cohort characteristics

Total cohort, n=52Responders, n=27Non-responders, n=22P values
Demographics
 Age (years, mean±SD)72.4±9.472.0±10.473.0±8.50.74
 Male (n,%)43 (82.7%)23 (85.2%)17 (77.3%)0.74
Device
 ICD: primary prevention (n, %)26 (78.8%)16 (88.9%)9 (64.3%)0.22
 Upgrade (n, %)14 (26.9%)5 (18.5%)9 (40.9%)0.16
Aetiology
 Ischaemic (n, %)30 (57.7%)15 (55.6%)13 (59.1%)1.00
 Non-ischaemic (n, %)22 (42.3%)12 (44.4%)9 (40.9%)
Comorbidities
 History of atrial fibrillation (n, %)28 (53.8%)14 (51.9%)12 (54.5%)1.00
 Diabetes mellitus (n, %)15 (28.8%)5 (18.5%)9 (40.9%)0.16
 COPD (n, %)10 (19.2%)3 (11.1%)6 (27.3%)0.28
 CKD (n, %)23 (44.2%)11 (40.7%)12 (54.5%)0.5
NYHA (n, %) II20 (38.5%)11 (40.7%)8 (36.4%)0.25
 III27 (51.9%)15 (55.6%)10 (45.5%)
 IV5 (9.6%)1 (3.7%)4 (18.2%)
Routine blood markers
 eGFR (mL/min/1.73 m2, median, range)61.5 (25.0–130.0)59 (25.0–130.0)58.0 (26.0–99.0)0.36
 Haemoglobin (g/L, mean±SD)134.4±13.5136.6±14.1132.5±12.50.28
 NT-pro-BNP (pmol/L, median, range)248.7 (53.0–4138.0)207.0 (53.0–4138.0)255.5 (67.0–547.0)0.37
 hs-TnT (ng/L, median, range)26.5 (6.5–233.0)26.4 (8.5–233.0)27.6 (6.5–61.8)0.78
Medications
 ACEi/ARB (n, %)50 (96.2%)26 (96.3%)21 (95.5%)1.00
 BB (n, %)44 (84.6%)22 (81.5%)21 (95.5%)0.24
 MRA (n, %)34 (65.4%)17 (63.0%)14 (63.6%)0.96
 Aspirin (n, %)24 (46.2%)13 (48.1%)9 (40.9%)0.83
 Clopidogrel (n, %)6 (11.5%)3 (11.1%)3 (13.6%)1.00
 Prasugrel (n, %)1 (1.9%)1 (3.7%)0 (0.0%)1.00
ECG
 Atrial Fibrillation (n, %)19 (36.5%)9 (33.3%)8 (36.4%)0.5
 QRS duration (ms, median, range)164.0 (120–240)168.0 (146–240)159.0 (120–210)0.11
 LBBB (n,%)39 (75.0%)23 (85.2%)14 (63.6%)0.16
QoL Score (median, range)48.5 (8–101)50 (9–86)48.5 (8–101)0.77
6MWT (M, mean±SD)238.8±130.6237.6±130.5239.4±127.40.95
Echocardiogram
 LVEDD (mm, mean±SD)*61.7±10.162.9±11.260.2±9.00.4
 LVESV (mL, median, range)*111.5 (49–219)119.3 (49–269)110.2 (56–169)0.41
 LVESV_BSA (mL, mean±SD)*61.3±21.565.7±25.856.6±16.30.26
 LVEF (%, mean±SD)*24.3±8.024.1±7.924.4±8.70.91
LV lead circumferential position (n, %)
 Anterior5 (9.6%)2 (7.4%)3 (13.6%)0.64
 Anterolateral3 (5.8%)2 (7.4%)1 (4.5%)
 Lateral28 (53.8%)13 (37.0%)13 (59.1%)
 Posterolateral16 (30.8%)10 (37.0%)5 (22.7%)
LV lead axial position
Basal (n, %)
29 (55.8%)15 (55.6%)11 (50.0%)0.7
 Mid-Cavity (n, %)23 (44.2%)12 (44.4%)11 (50.0%)
  • ~ = proportion of patients with defibrillators only,

  • *Represents data available.

  • ACEi, angiotension converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; BSA, body surface area; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; LVEDV, LV end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, LV end systolic diameter; LVESV, left ventricular end systolic volume; LVIDD, LV end diastolic diameter; MI, myocardial Infarction; MRA, mineral corticoid receptor antagonist; PCI, percutaneous coronary intervention; QoL, Qualiy of Life.